Results 101 to 110 of about 2,707 (157)

Bedaquiline or delamanid improves the quality of life among patients with drug-resistant tuberculosis. [PDF]

J Family Med Prim Care
Putra ON, Purnamasari T.
europepmc   +1 more source

Delamanid als Add-on bei multiresistenter Tuberkulose [PDF]

Pneumologie, 2019
openaire   +1 more source

Clinical and bacterial determinants of unfavorable tuberculosis treatment outcomes: an observational study in Georgia. [PDF]

Genome Med
Goig GA, Loiseau C, Maghradze N, Mchedlishvili K, Avaliani T, Tsutsunava A, Brites D, Kalkan S, Borrell S, Aspindzelashvili R, Avaliani Z, Kipiani M, Tukvadze N, Jugheli L, Gagneux S.   +14 more
europepmc   +1 more source

Characterizing the performance of an antibiotic resistance prediction tool, gnomonicus, using a diverse test set of 2,663 <i>Mycobacterium tuberculosis</i> samples. [PDF]

Microb Genom
Westhead J, Baker CS, Brouard M, Colpus M, Constantinides B, Hall A, Knaggs J, Alves ML, Spies R, Thai H, Surrall S, Govender K, Peto TEA, Crook DW, Omar SV, Turner R, Fowler PW.   +16 more
europepmc   +1 more source

Epidemiology and Outcomes of Pediatric Multidrug-resistant Tuberculosis in Namibia: A Retrospective Review of National Registry Data From 2013 to 2023. [PDF]

Pediatr Infect Dis J
Burkhardt I, Ruswa N, Iitana M, Ekandjo H, Claassens MM, Nepolo E, Aebi C, Seddon JA, Günther G.   +8 more
europepmc   +1 more source

The Frequency and Incidence of QT Prolongation With Extended Use of Bedaquiline or Delamanid in a Large, Multi-Country Multidrug-Resistant/Rifampicin-Resistant Tuberculosis Cohort. [PDF]

Clin Infect Dis
Khan U, Rich M, Franke MF, Lachenal N, Ahmed S, Bekele A, Isani AK, Hewison C, Sari CYI, Tan CL, Varaine F, Flores EH, Putri FA, Faqirzai J, Beauchamp J, Vo LNQ, Siddiqui MR, Seung K, Bastard M, Nkunkanyirazo P, Kiria N, Khan M, Algozhin Y, Melikyan N, Saki NA, Vilbrun SC, Fatima R, Naing YY, Islam S, Mamsa S, Mitnick CD, Huerga H, Khan PY.   +32 more
europepmc   +1 more source

Investigation of delamanid, bedaquiline, and linezolid resistance rates and related gene mutations in multidrug-resistant Mycobacterium tuberculosis in regional tuberculosis reference laboratories of Iran. [PDF]

BMC Microbiol
Ahmad Khosravi N, Khosravi AD, Hashemzadeh M, Savari M, Saki M.   +4 more
europepmc   +1 more source

Efficacy and safety of an all-oral delamanid-containing regimen in the treatment of multidrug-resistant pulmonary tuberculosis complicated by extrapulmonary tuberculosis: Four case reports and review of the literature. [PDF]

J Clin Tuberc Other Mycobact Dis
Hu X, Cheng C, Jin Q, Jin W, Dong Q, Wu F, Hu F, Li Y, Wang L, Lu L, Xu Q, Du J.   +11 more
europepmc   +1 more source

Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB. [PDF]

J Antimicrob Chemother
Koele SE, Stoycheva K, Mtweve C, Manyama C, Mpagama S, Mhimbira F, Wallis R, Ntinginya NE, Liyoyo A, Huglin B, Minja LT, Wagnerberger L, Zumba T, Noreña I, Peter DD, Beattie T, Makkan H, Sloan DJ, Te Brake L, Aarnoutse RE, McHugh TD, Wildner L, Schildkraut J, Aldana BH, Phillips PPJ, Hoelscher M, Svensson EM, Heinrich N, PanACEA consortium .   +28 more
europepmc   +1 more source